Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $44.38 Average PT from Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $44.3750.

EYPT has been the topic of several research reports. Royal Bank Of Canada dropped their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Chardan Capital reiterated a “buy” rating and set a $65.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Friday, August 7th. Cantor Fitzgerald increased their price target on Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Guggenheim reissued a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Finally, HC Wainwright dropped their price target on Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th.

Eyepoint Pharmaceuticals Stock Performance

EYPT opened at $14.75 on Monday. The company’s 50-day simple moving average is $13.23 and its two-hundred day simple moving average is $13.70. The stock has a market capitalization of $1.27 billion, a P/E ratio of -3.94 and a beta of 1.76. Eyepoint Pharmaceuticals has a 52-week low of $9.65 and a 52-week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Research analysts forecast that Eyepoint Pharmaceuticals will post -3.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. KBC Group NV bought a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $76,000. Tower Research Capital LLC TRC lifted its stake in shares of Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after purchasing an additional 5,967 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.